News >

Precision Medicine: The Next Paradigm Shift in MCL

Caroline Seymour
Published: Sunday, May 17, 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center

Michael Wang, MD

The field of lymphoma has undergone a dramatic paradigm shift from the use of chemotherapy to targeted therapy to immunotherapy, and now, to cellular therapy, said Michael Wang, MD, who added that the future landscape will be driven by precision medicine in which mechanisms of resistance are well understood, particularly in aggressive subtypes, such as mantle cell lymphoma (MCL).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication